论文部分内容阅读
1990年12月起日本开始对助血员用第一代ELISA筛检抗-HCV,1992年2月后应用核心区c22、非结构区c 33 c和c 100-3等抗原加上RIBA作补充使敏感性和特异性均有提高。检测结果显示,日本抗-HCV的血清阳性率与年龄显著相关:20岁以下者抗-HCV血清阳性率为0.2％,其后每10岁年龄段分别为0.7％、1.9％、2.6％,50岁以上则达到3.9％。估计全日本有230万人通过污染血液感染HCV,事实上真正数字还要高,因为65岁以上者未计入而这些人的阳性率则更高。作者观察537例医务人员中有16例抗-HCV阳性。其中,3例仅ELISA法检出c 100-3阳性,而用RIBA法检测抗-HCV和用PCR法检测HCV RNA
In December 1990, Japan started to screen anti-HCV for first-generation blood clots by blood donors. After February 1992, core antigen c22, non-structural c33 c and c 100-3 antigens were added together with RIBA Increased sensitivity and specificity. The results showed that the seroprevalence of anti-HCV in Japan was significantly correlated with age: the anti-HCV seroprevalence was less than 0.2% in patients younger than 20 years old, followed by 0.7%, 1.9%, 2.6%, 50% 3.9% above the age of. It is estimated that 2.3 million people in Japan throughout the country contaminated by contaminated blood HCV, in fact, the real figure is even higher, because more than 65 years of age were not included in these people and the positive rate is even higher. The authors observed 16 of 537 medical staff were anti-HCV positive. Among them, only 3 cases of c 100-3 positive ELISA method, and RIBA anti-HCV and PCR detection of HCV RNA